Abstract:Background:Depression is a serious psychiatric disorder that creates a major public health burden of disease and disability. It is quite widespread;approximately 16% of individuals in the United States have suffered from clinical depression during their lifetime. While antidepressants have been available for several decades,most of them are not totally effective. New approaches to clinically treating depression are thus needed,and the molecular and cellular mechanisms underlying the pathophysiology of depression could provide a new therapeutic target. Cyclin-dependent kinase 5 (Cdk5),is a proline-directed serine/threonine kinase that is highly active in the brain and is important for the development of the central nervous system. Cdk5 has been implicated in synaptic plasticity,which underlies learning and memory,as well as neuropsychiatric pathologies like depression and bipolar disorder. Recently,it also has been reported that inhibition of Cdk5 activity in the hippocampus facilitates extinction of learned contextual fear memory,suggesting that Cdk5 could be a potential target for treatment of emotional disorders. However,hippocampal Cdk5’s potential role in the development of depressive diseases has not been examined.Objectives:To investigate the possible roles that Cdk5/p35 might play in the development of depressive-like symptoms,using the chronic mild stress rat model. Methods:Two hundred and ninety-two male Sprague-Dawley rats (weighing 200-220 g at the start of the study) were individually housed under a constant temperature (23±s 2 degrees Celsius) and maintained on a 12 h light/dark cycle with free access to food and water. In order to examine the effects of Cdk5/p35 activity in hippocampus on depressive-like behavior,rats were subjected to the chronic mild stress procedure for 3 weeks. Subsequently,the depressive-like behaviors including sucrose preference,bodyweight increase and locomotor activity were examined;Cdk5 kinase activity was measured by an in vitro phosphorylation assay,and membrane and cytosolic p35 levels were detected by Western blot analysis. In order to investigate whether Cdk5 is functionally related to the depressive-like symptoms elicited by the CMS procedure,Buty,a Cdk5 inhibitor,was infused into DG,CA1 and CA3 subfield,respectively. Over the next 3 weeks,they received injections in DG,CA1 or CA3 on days 1,7,14 and 21,as detailed in a previous study. The control groups received intra-DG,CA1 or CA3 injection of saline containing 0.2% DMSO or different doses of Buty (25,50 and 100 ng). The chronic mild stress groups were given intra-DG,CA1 or CA3 injections of saline containing 0.2% DMSO and different doses of Buty (25,50 and 100 ng) during the 3 weeks of chronic mild stress. Each intracranial injection was administrated between 8.00-10.00 am,1 h prior to stress exposure to the stressor. The day after the last stress exposure,the sucrose preference test was performed and then the animals were decapitated. Subsequently,bilateral tissue punches from CA1,CA3 and DG (16 gauge) were obtained. Proteins were extracted for kinase activity measurement and Western blot assay. The subsequent experiment was designed to determine the role p35 translocation plays in the actions of antidepressants. Four groups of rats (n=8 per group) were used to examine effects of the antidepressant venlafaxine on DG p35 translocation using a 2×2 design with the between-subject factors of Group (Control or CMS) and Treatment (vehicle or venlafaxine). The other four groups of rats (n=8 per group) were used to examine the effects of the antidepressant mirtazapine on DG p35 translocation using a 2×2 design,with the between-subject factors Group (Control or CMS) and Treatment (vehicle or mirtazapine). Intraperitoneal drug or vehicle injections were performed for 21 consecutive days in both the control and CMS groups. The day after the last stress exposure,the sucrose preference test was performed and the animals were decapitated. Subsequently,bilateral DG tissue punches (16 gauge) were obtained. The cytoplasmic and membrane protein levels were measured by Western blot assay. Results:CMS increased hippocampal Cdk5 activity,which was accompanied by an upregulation of membrane p35,a Cdk5 activator,and a reduction of cytosolic p35 in the dentate gyrus (DG). Microinjection of a Cdk5 inhibitor,butyrolactone,in DG,but not in CA1 or CA3,reversed the depressive-like behaviors induced by CMS. A negative linear correlation was found between sucrose preference,bodyweight increase and the membrane p35 level in DG. Chronic treatment with antidepressants venlafaxine and mirtazapine,but not the antipsychotic aripiprazole,prevented the aberrant translocation of p35 induced by CMS in DG. Conclusion:Our results revealed that the development of depressive-like behavior was associated with increased Cdk5 activity through p35 translocation from the cytosol to the membrane in DG. These findings suggest that hippocampal Cdk5/p35 complex mediated the depressive-like behavior induced by CMS;thus,Cdk5 could be a novel target for therapeutic treatment of major depression.

Continuous GSK-3β overexpression in the hippocampal dentate gyrus induces prodepressant-like effects and increases sensitivity to chronic mild stress in mice.

Microglial glutaminase 1 mediates chronic restraint stress-induced depression-like behaviors and synaptic damages

Microglial Glutaminase 1 Deficiency Mitigates Neuroinflammation Associated Depression.

GSK-3β Deletion in Dentate Gyrus Excitatory Neuron Impairs Synaptic Plasticity and Memory

Effects of Hippocampal PGC-1α on Depression-Like Behaviors and Number of Astrocytes in Hippocampal Subregions in Mice

CYCLIN-DEPENDENT KINASE 5 IN THE DENTATE GYRUS MEDIATES DEPRESSIVE-LIKE BEHAVIOR IN RATS

Effects of glycogen synthase kinase-3 activity inhibition on cognitive, behavioral, and hippocampal ultrastructural deficits in adulthood associated with adolescent methamphetamine exposure

PGC-1α in the hippocampus mediates depressive-like and stress-coping behaviours and regulates excitatory synapses in the dentate gyrus in mice

Behavioral and [F-18] Fluorodeoxyglucose Micro Positron Emission Tomography Imaging Study in a Rat Chronic Mild Stress Model of Depression

Effects of Different CMS on Behaviors, BDNF/CREB/Bcl-2 Expression in Rat Hippocampus

Citalopram Alleviates Chronic Stress Induced Depression-Like Behaviors in Rats by Activating GSK3β Signaling in Dorsal Hippocampus.

Synapse differentiation-induced gene 1 regulates stress-induced depression through interaction with the AMPA receptor GluA2 subunit of nucleus accumbens in male mice

Deficiency of Glycosylated-Α-dystroglycan in Ventral Hippocampus Bridges the De-Stabilization of Gamma-Aminobutyric Acid Type A Receptors with the Depressive-Like Behaviors of Male Mice

Mir-138 Increases Depressive-Like Behaviors by Targeting SIRT1 in Hippocampus

The effect of citalopram on chronic stress-induced depressive-like behavior in rats through GSK3β/β-catenin activation in the medial prefrontal cortex

Effects of CRMP2 DNA Methylation in the Hippocampus on Depressive-Like Behaviors and Cytoskeletal Proteins in Rats

GLS1 Mutant Mice Display Moderate Alterations of Hippocampal Glutamatergic Neurotransmission Associated with Specific Adaptive Behavioral Changes

Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor Sb216763, in the Chronic Mild Stress Model of Mice

Hippocampal SENP3 mediates chronic stress-induced depression-like behaviors by impairing the CREB-BDNF signaling

Obligatory role of microglia-mobilized hippocampal CREB-BDNF signaling in the prophylactic effect of β-glucan on chronic stress-induced depression-like behaviors in mice

Dlg1 deletion in microglia ameliorates chronic restraint stress induced mice depression-like behavior